Coston McIsaac & Partners Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Coston McIsaac & Partners lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 37,483 shares of the company’s stock after purchasing an additional 924 shares during the quarter. Johnson & Johnson accounts for approximately 1.7% of Coston McIsaac & Partners’ investment portfolio, making the stock its 19th largest position. Coston McIsaac & Partners’ holdings in Johnson & Johnson were worth $6,074,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Innealta Capital LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $27,000. MFA Wealth Advisors LLC bought a new stake in Johnson & Johnson in the second quarter worth $43,000. Fairfield Financial Advisors LTD purchased a new position in Johnson & Johnson during the second quarter worth $46,000. Fairway Wealth LLC raised its stake in shares of Johnson & Johnson by 217.1% in the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after acquiring an additional 228 shares during the period. Finally, Quarry LP bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $49,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on JNJ shares. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group reduced their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. TD Cowen reduced their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, Citigroup upped their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Price Performance

NYSE JNJ opened at $165.86 on Thursday. The company has a market cap of $399.17 billion, a PE ratio of 10.34, a P/E/G ratio of 2.65 and a beta of 0.52. The firm’s 50 day moving average price is $163.29 and its 200-day moving average price is $154.92. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.66 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 2.99%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 30.92%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.